Pharmaceutical New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list the anesthesia reversal agent sugammadex (Bridion, from US pharma giant Merck & Co; NYSE; MRK) in Section H of the Pharmaceutical Schedule (the national Preferred Medicines List (PML), subject to the restrictions outlined below, from July 1, 2013, through a provisional agreement with the US firm's local subsidiary Merck Sharp & Dohme as follows: 30 January 2013